What is ARCT's current stock price?

ARCT (Arcturus Therapeutics Holdings Inc.) is currently trading at $7.03 with a market cap of $199.8M.

What sector is Arcturus Therapeutics Holdings Inc. in?

Arcturus Therapeutics Holdings Inc. (ARCT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ARCT a good stock to buy?

Analysts have a Buy consensus on ARCT with a price target of $22.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ARCT Arcturus Therapeutics Holdings Inc.

Healthcare

$7.03+0.14%ClosedMarket Cap: $199.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.04

P/S

4.41

EV/EBITDA

-0.11

DCF Value

$-5.45

FCF Yield

-29.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

91.2%

Operating Margin

-196.7%

Net Margin

-173.5%

ROE

-36.6%

ROA

-32.1%

ROIC

-42.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$610.0K	$-27.0M	$—
Q4 null	$3.1M	$-29.1M	$—
FY null	$67.2M	$-65.8M	$—
Q3 null	$17.2M	$-13.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$22.50

Target (Median)

$22.50

Target Range

$20.00 - $25.00

2 Strong Buy8 Buy3 Hold0 Sell0 Strong Sell

B. Riley SecuritiesBuy

2026-03-18

CitigroupBuy

2026-03-05

Piper SandlerOverweight

2026-03-04

CitigroupNeutral

2026-03-04

CitigroupNeutral

2026-01-06

Trading Activity

Insider Trades

View All

MULROY DENNISofficer: Chief Financial Officer

SellThu May 07

MULROY DENNISofficer

SellThu May 07

Roberts Josephofficer: Controller

SellFri Dec 19

Roberts Josephofficer: Controller

SellFri Dec 19

Roberts Josephofficer: Controller

SellFri Dec 19

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.42

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Peers